<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39136010</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>The longitudinal characterization of immune responses in COVID-19 patients reveals novel prognostic signatures for disease severity, patients' survival and long COVID.</ArticleTitle><Pagination><StartPage>1381091</StartPage><MedlinePgn>1381091</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1381091</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1381091</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">SARS-CoV-2 pandemic still poses a significant burden on global health and economy, especially for symptoms persisting beyond the acute disease. COVID-19 manifests with various degrees of severity and the identification of early biomarkers capable of stratifying patient based on risk of progression could allow tailored treatments.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We longitudinally analyzed 67 patients, classified according to a WHO ordinal scale as having Mild, Moderate, or Severe COVID-19. Peripheral blood samples were prospectively collected at hospital admission and during a 6-month follow-up after discharge. Several subsets and markers of the innate and adaptive immunity were monitored as putative factors associated with COVID-19 symptoms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">More than 50 immunological parameters were associated with disease severity. A decision tree including the main clinical, laboratory, and biological variables at admission identified low NK-cell precursors and CD14<sup>+</sup>CD91<sup>+</sup> monocytes, and high CD8<sup>+</sup> Effector Memory T cell frequencies as the most robust immunological correlates of COVID-19 severity and reduced survival. Moreover, low regulatory B-cell frequency at one month was associated with the susceptibility to develop long COVID at six months, likely due to their immunomodulatory ability.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">These results highlight the profound perturbation of the immune response during COVID-19. The evaluation of specific innate and adaptive immune-cell subsets allows to distinguish between different acute and persistent COVID-19 symptoms.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Noviello, De Lorenzo, Chimienti, Maugeri, De Lalla, Siracusano, Lor&#xe8;, Rancoita, Cugnata, Tassi, Dispinseri, Abbati, Beretta, Ruggiero, Manfredi, Merolla, Cantarelli, Tresoldi, Pastori, Caccia, Sironi, Marzinotto, Saliu, Ghezzi, Lampasona, Vicenzi, Cinque, Manfredi, Scarlatti, Dellabona, Lopalco, Di Serio, Malnati, Ciceri, Rovere-Querini and Bonini.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Noviello</LastName><ForeName>Maddalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Experimental Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cell Therapy Immunomonitoring Laboratory Monitoraggio Immunologico Terapie Cellulari (MITiCi), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>De Lorenzo</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chimienti</LastName><ForeName>Raniero</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Viral Evolution and Transmission Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maugeri</LastName><ForeName>Norma</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Autoimmunity and Vascular Inflammation Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Lalla</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Experimental Immunology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siracusano</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Immunobiology of Human Immunodeficiency Virus (HIV) Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lor&#xe8;</LastName><ForeName>Nicola Ivan</ForeName><Initials>NI</Initials><AffiliationInfo><Affiliation>Emerging Bacterial Pathogens Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rancoita</LastName><ForeName>Paola Maria Vittoria</ForeName><Initials>PMV</Initials><AffiliationInfo><Affiliation>University Centre for Statistics in the Biomedical Sciences (CUSSB), Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cugnata</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University Centre for Statistics in the Biomedical Sciences (CUSSB), Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tassi</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Experimental Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cell Therapy Immunomonitoring Laboratory Monitoraggio Immunologico Terapie Cellulari (MITiCi), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dispinseri</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Viral Evolution and Transmission Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbati</LastName><ForeName>Danilo</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Experimental Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beretta</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Experimental Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cell Therapy Immunomonitoring Laboratory Monitoraggio Immunologico Terapie Cellulari (MITiCi), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruggiero</LastName><ForeName>Eliana</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Experimental Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manfredi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Experimental Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merolla</LastName><ForeName>Aurora</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantarelli</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Biological Resource Center Centro Risorse Biologiche-Ospedale San Raffaele (CRB-OSR), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tresoldi</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biological Resource Center Centro Risorse Biologiche-Ospedale San Raffaele (CRB-OSR), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastori</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Immunobiology of Human Immunodeficiency Virus (HIV) Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caccia</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neurovirology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sironi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Viral Evolution and Transmission Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marzinotto</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Diabetes Research Institute, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saliu</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Emerging Bacterial Pathogens Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghezzi</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Viral Pathogenesis and Biosafety Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lampasona</LastName><ForeName>Vito</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Diabetes Research Institute, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vicenzi</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Viral Pathogenesis and Biosafety Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cinque</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neurovirology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manfredi</LastName><ForeName>Angelo Andrea</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Autoimmunity and Vascular Inflammation Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarlatti</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Viral Evolution and Transmission Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dellabona</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Experimental Immunology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopalco</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Immunobiology of Human Immunodeficiency Virus (HIV) Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Serio</LastName><ForeName>Clelia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University Centre for Statistics in the Biomedical Sciences (CUSSB), Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malnati</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Viral Evolution and Transmission Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ciceri</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hematology and Bone Marrow Transplant Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Rovere-Querini</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bonini</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Experimental Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cell Therapy Immunomonitoring Laboratory Monitoraggio Immunologico Terapie Cellulari (MITiCi), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056704" MajorTopicYN="N">Adaptive Immunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 patients&#x2019; survival</Keyword><Keyword MajorTopicYN="N">COVID-19 severity</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 adaptive immunity</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 innate immunity</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>13</Day><Hour>4</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39136010</ArticleId><ArticleId IdType="pmc">PMC11317765</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1381091</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Planas D, Saunders N, Maes P, Guivel-benhassine F, Planchais C, Buchrieser J, et al. . Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. (2022) 602:671&#x2013;5. doi:&#xa0;10.1038/s41586-021-04389-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04389-z</ArticleId><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, et al. . The evolution of SARS-coV-2. Nat Rev Microbiol. (2023) 21:361&#x2013;79. doi:&#xa0;10.1038/s41579-023-00878-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Augello M, Bono V, Rovito R, Tincati C, Marchetti G. Immunologic interplay between HIV/AIDS and COVID&#x2212;19: adding fuel to the flames? Curr HIV/AIDS Rep. (2023) 20(2):51&#x2013;75. doi:&#xa0;10.1007/s11904-023-00647-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11904-023-00647-z</ArticleId><ArticleId IdType="pmc">PMC9860243</ArticleId><ArticleId IdType="pubmed">36680700</ArticleId></ArticleIdList></Reference><Reference><Citation>Corradini P, Agrati C, Apolone G, Mantovani A, Giannarelli D, Marasco V, et al. . Humoral and T-cell immune response after 3 doses of messenger RNA severe acute respiratory syndrome coronavirus 2 vaccines in fragile patients: the italian VAX4FRAIL study. Clin Infect Dis. (2023) 76:426&#x2013;38. doi:&#xa0;10.1093/cid/ciac404</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac404</ArticleId><ArticleId IdType="pmc">PMC9213871</ArticleId><ArticleId IdType="pubmed">35607769</ArticleId></ArticleIdList></Reference><Reference><Citation>Wouters OJ, Shadlen KC, Salcher-konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, et al. . Health Policy Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. (2021) 397:1023&#x2013;34. doi:&#xa0;10.1016/S0140-6736(21)00306-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00306-8</ArticleId><ArticleId IdType="pmc">PMC7906643</ArticleId><ArticleId IdType="pubmed">33587887</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraccioli G, Gremese E, Goletti D, Petrone L, Cantini F, Ugel S, et al. . Immune-guided therapy of COVID-19. Cancer Immunol Res. (2022) 10(4):384&#x2013;402. doi:&#xa0;10.1158/2326-6066.CIR-21-0675</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-21-0675</ArticleId><ArticleId IdType="pubmed">35074758</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. . Clinical characteristics of 3062 COVID - 19 patients: A meta - analysis. J Med Virol. (2020) 92:1902&#x2013;14. doi:&#xa0;10.02/jmv.25884</Citation><ArticleIdList><ArticleId IdType="doi">10.02/jmv.25884</ArticleId><ArticleId IdType="pmc">PMC7262119</ArticleId><ArticleId IdType="pubmed">32293716</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovito R, Augello M, Ben-haim A, Bono V, Monforte A, Marchetti G. Hallmarks of severe COVID-19 pathogenesis: A pas de deux between viral and host factors. Front Immunol. (2022) 13:912336. doi:&#xa0;10.3389/fimmu.2022.912336</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.912336</ArticleId><ArticleId IdType="pmc">PMC9231592</ArticleId><ArticleId IdType="pubmed">35757770</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID - 19) implicate special control measures. J Med Virol. (2020) 92:568&#x2013;76. doi:&#xa0;10.1002/jmv.25748</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25748</ArticleId><ArticleId IdType="pmc">PMC7228347</ArticleId><ArticleId IdType="pubmed">32134116</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Koulouris N, Gogos C, et al. . Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. (2020) 27:992&#x2013;1000.e3. doi:&#xa0;10.1016/j.chom.2020.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.009</ArticleId><ArticleId IdType="pmc">PMC7172841</ArticleId><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronte V, Brandau S, Chen S, Colombo MP, Frey AB, Greten TF, et al. . Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. (2016) 7:12150. doi:&#xa0;10.1038/ncomms12150</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12150</ArticleId><ArticleId IdType="pmc">PMC4935811</ArticleId><ArticleId IdType="pubmed">27381735</ArticleId></ArticleIdList></Reference><Reference><Citation>Unterman A, Sumida TS, Nouri N, Yan X, Zhao AY, Gasque V, et al. . Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. Nat Commun. (2022) 13(1):440. doi:&#xa0;10.1038/s41467-021-27716-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27716-4</ArticleId><ArticleId IdType="pmc">PMC8782894</ArticleId><ArticleId IdType="pubmed">35064122</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciceri F, Castagna A, Rovere-querini P, Cobelli F, Ruggeri A, Galli L, et al. . Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol. (2020) 217:108509. doi:&#xa0;10.1016/j.clim.2020.108509</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108509</ArticleId><ArticleId IdType="pmc">PMC7289745</ArticleId><ArticleId IdType="pubmed">32535188</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu J, Sareli C, Mayer D, Visbal A, Sareli A. Lymphopenia as a predictor for adverse clinical outcomes in hospitalized patients with COVID-19: A single center retrospective study of 4485 cases. J Clin Med. (2022) 11(3):700. doi:&#xa0;10.3390/jcm11030700</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11030700</ArticleId><ArticleId IdType="pmc">PMC8837002</ArticleId><ArticleId IdType="pubmed">35160150</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Zhao J, Ning Q, Chen G, Wu D, Guo W, et al. . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. (2020) 130:2620&#x2013;9. doi:&#xa0;10.1172/JCI137244</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreutmair S, Unger S, Bitzer M, Roquilly A. Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia ll Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia. Immunity. (2021) 54(7):1578&#x2013;93. doi:&#xa0;10.1016/j.immuni.2021.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.05.002</ArticleId><ArticleId IdType="pmc">PMC8106882</ArticleId><ArticleId IdType="pubmed">34051147</ArticleId></ArticleIdList></Reference><Reference><Citation>Atyeo C, Fischinger S, Zohar T, Lauffenburger D, Chu H, Atyeo C, et al. . Distinct early serological signatures track with SARS-coV-2 survival. Immunity. (2020) 53:524&#x2013;532.e4. doi:&#xa0;10.1016/j.immuni.2020.07.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.07.020</ArticleId><ArticleId IdType="pmc">PMC7392190</ArticleId><ArticleId IdType="pubmed">32783920</ArticleId></ArticleIdList></Reference><Reference><Citation>Secchi M, Piemonti L, Lampasona V, Secchi M, Bazzigaluppi E, Brigatti C, et al. . COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. J Clin Invest. (2020) 130(12):6366&#x2013;78. doi:&#xa0;10.1172/JCI142804</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI142804</ArticleId><ArticleId IdType="pmc">PMC7685720</ArticleId><ArticleId IdType="pubmed">32991329</ArticleId></ArticleIdList></Reference><Reference><Citation>Dispinseri S, Secchi M, Pirillo MF, Tolazzi M, Borghi M, Brigatti C, et al. . Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat Commun. (2021) 12:2670. doi:&#xa0;10.1038/s41467-021-22958-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22958-8</ArticleId><ArticleId IdType="pmc">PMC8113594</ArticleId><ArticleId IdType="pubmed">33976165</ArticleId></ArticleIdList></Reference><Reference><Citation>Siracusano G, Brombin C, Pastori C, Cugnata F, Maugeri N, Bozzi C, et al. . Profiling antibody response patterns in COVID-19: spike S1-reactive igA signature in the evolution of SARS-coV-2 infection. Front Immunol. (2021) 12:772239. doi:&#xa0;10.3389/fimmu.2021.772239</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.772239</ArticleId><ArticleId IdType="pmc">PMC8595940</ArticleId><ArticleId IdType="pubmed">34804064</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X. Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients. Clin Infect Dis. (2020) 71(10):2688&#x2013;94. doi:&#xa0;10.1093/cid/ciaa721</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa721</ArticleId><ArticleId IdType="pmc">PMC7314147</ArticleId><ArticleId IdType="pubmed">32497196</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao C, Bora SA, Parimon T, Gharib SA, Goodridge HS, Chen P, et al. . Cell-type-specific immune dysregulation in severely ill COVID-19 patients ll cell-type-specific immune dysregulation in severely ill COVID-19 patients. Cell Rep. (2021) 34(1):108590. doi:&#xa0;10.1016/j.celrep.2020.108590</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108590</ArticleId><ArticleId IdType="pmc">PMC7744012</ArticleId><ArticleId IdType="pubmed">33357411</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovito R, Bono V, Augello M, Tincati C, Mainoldi F, Bussi&#xe8;res GB, et al. . Association between SARS&#x2212;CoV&#x2212;2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID&#x2212;19 patients. Sci Rep. (2022) 12(1):19658. doi:&#xa0;10.1038/s41598-022-23923-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-23923-1</ArticleId><ArticleId IdType="pmc">PMC9667450</ArticleId><ArticleId IdType="pubmed">36385627</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko N, Kuo H, Boucau J, Padera RF, Kaneko N, Kuo H, et al. . Article loss of bcl-6-expressing T follicular helper cells and germinal centers in COVID-19 ll article loss of bcl-6-expressing T follicular helper cells and germinal centers in COVID-19. Cell. (2020) 183(1):143&#x2013;57. doi:&#xa0;10.1016/j.cell.2020.08.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.025</ArticleId><ArticleId IdType="pmc">PMC7437499</ArticleId><ArticleId IdType="pubmed">32877699</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. . Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. (2021) 371(6529):4063. doi:&#xa0;10.1126/science.abf4063</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4063</ArticleId><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. . COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses. Nature. (2020) 586:594&#x2013;99. doi:&#xa0;10.1038/s41586-020-2814-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2814-7</ArticleId><ArticleId IdType="pubmed">32998157</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A, Crotty S. Adaptive immunity to SARS-coV-2 and COVID-19. Cell. (2021) 184:861&#x2013;80. doi:&#xa0;10.1016/j.cell.2021.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.007</ArticleId><ArticleId IdType="pmc">PMC7803150</ArticleId><ArticleId IdType="pubmed">33497610</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. . Articles Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 6736:1&#x2013;9. doi:&#xa0;10.1016/S0140-6736(20)30566-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Moderbacher CR, Ramirez SI, Dan JM, Smith DM, Sette A, Moderbacher CR, et al. . Article antigen-specific adaptive immunity to SARS-coV-2 in acute COVID-19 and associations with age and disease severity ll antigen-specific adaptive immunity to SARS-coV-2 in acute COVID-19 and associations with age and disease severity. Cell. (2020) 183:996&#x2013;1012.e19. doi:&#xa0;10.1016/j.cell.2020.09.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.038</ArticleId><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Lor&#xe8; NI, De Lorenzo R, Rancoita PMV, Cugnata F, Agresti A, Benedetti F, et al. . CXCL10 levels at hospital admission predict COVID&#x2212;19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study. Mol Med. (2021) 27:1&#x2013;10. doi:&#xa0;10.1186/s10020-021-00390-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-021-00390-4</ArticleId><ArticleId IdType="pmc">PMC8521494</ArticleId><ArticleId IdType="pubmed">34663207</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y, et al. . The signal pathways and treatment of cytokine storm in COVID-19. Sig Transduct Target Ther. (2021) 6:255. doi:&#xa0;10.1038/s41392-021-00679-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00679-0</ArticleId><ArticleId IdType="pmc">PMC8261820</ArticleId><ArticleId IdType="pubmed">34234112</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhang D, Du PG, Du PR, Zhao PJ, Jin PY, et al. . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. (2020) 6736:1&#x2013;10. doi:&#xa0;10.1016/S0140-6736(20)31022-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31022-9</ArticleId><ArticleId IdType="pmc">PMC7190303</ArticleId><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, Wang D, Chen C, Lu W, Liu H, Lv T. PaO 2/FiO 2 and IL &#x2212; 6 are risk factors of mortality for intensive care COVID &#x2212; 19 patients. Sci Rep. (2021) 11:7334. doi:&#xa0;10.1038/s41598-021-86676-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-86676-3</ArticleId><ArticleId IdType="pmc">PMC8016870</ArticleId><ArticleId IdType="pubmed">33795768</ArticleId></ArticleIdList></Reference><Reference><Citation>Peckham H, De Gruijter NM, Ciurtin C, Wedderburn LR, Deakin CT, Raine C, et al. . Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. (2020) 11:6317. doi:&#xa0;10.1038/s41467-020-19741-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19741-6</ArticleId><ArticleId IdType="pmc">PMC7726563</ArticleId><ArticleId IdType="pubmed">33298944</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee R, Kanti Barman P, Kumar Thatoi P, Tripathy R, Das BK, Ravindran B, et al. . Non-Classical monocytes display inflammatory features: Validation in Sepsis and Systemic Lupus Erythematous. Sci Rep. (2015) 5:13886. doi:&#xa0;10.1038/srep13886</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep13886</ArticleId><ArticleId IdType="pmc">PMC4566081</ArticleId><ArticleId IdType="pubmed">26358827</ArticleId></ArticleIdList></Reference><Reference><Citation>Piquero-casals J, Mart&#xed;nez-mart&#xed;nez L, Agust&#xed;n A, Rozas-mu&#xf1;oz E, Juarez C, Puig L. LRP1/CD91 is highly expressed in monocytes from patients with vitiligo &#x2013; even after repigmentation. Exp Dermatol. (2021) 30(3):390&#x2013;5. doi:&#xa0;10.1111/exd.14249</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/exd.14249</ArticleId><ArticleId IdType="pubmed">33249636</ArticleId></ArticleIdList></Reference><Reference><Citation>Trombetta A, Farias GB, Gomes AMC, Godinho-Santos A, Rosmaninho P, Conceic CM, et al. . Severe COVID-19 recovery is associated with timely acquisition of a myeloid cell immune-regulatory phenotype. Front Immunol. (2021) 12:691725. doi:&#xa0;10.3389/fimmu.2021.691725</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.691725</ArticleId><ArticleId IdType="pmc">PMC8265310</ArticleId><ArticleId IdType="pubmed">34248984</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruenjaiman V, Sodsai P, Kueanjinda P, Bunrasmee W, Klinchanhom S, Reantragoon R, et al. . Impact of SARS-CoV-2 infection on the profiles and responses of innate immune cells after recovery. J Microbiol Immunol Infection. (2022) 55:993&#x2013;1004. doi:&#xa0;10.1016/j.jmii.2022.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2022.09.001</ArticleId><ArticleId IdType="pmc">PMC9519362</ArticleId><ArticleId IdType="pubmed">36220753</ArticleId></ArticleIdList></Reference><Reference><Citation>Della-Torre E, Lanzillotta M, Campochiaro C, Cavalli G, De Luca G, Tomelleri A, et al. . Respiratory impairment predicts response to IL-1 and IL-6 blockade in COVID-19 patients with severe pneumonia and hyper-inflammation. Front Immunol. (2021) 12:675678. doi:&#xa0;10.3389/fimmu.2021.675678</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.675678</ArticleId><ArticleId IdType="pmc">PMC8117339</ArticleId><ArticleId IdType="pubmed">33995419</ArticleId></ArticleIdList></Reference><Reference><Citation>Villaescusa L, Zaragoz&#xe1; F, Gayo-Abeleira I, Zaragoz&#xe1; C. A new approach to the management of COVID-19. Antagonists of IL-6: siltuximab. Adv Ther. (2022) 39:1126&#x2013;48. doi:&#xa0;10.1007/s12325-022-02042-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-022-02042-3</ArticleId><ArticleId IdType="pmc">PMC8784859</ArticleId><ArticleId IdType="pubmed">35072887</ArticleId></ArticleIdList></Reference><Reference><Citation>Amand M, Iserentant G, Poli A, Sleiman M, Fievez V, Sanchez IP, et al. . Human CD56 dim CD16 dim Cells As an Individualized Natural Killer Cell Subset. Front Immunol. (2017) 8:699. doi:&#xa0;10.3389/fimmu.2017.00699</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00699</ArticleId><ArticleId IdType="pmc">PMC5474676</ArticleId><ArticleId IdType="pubmed">28674534</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer J. CD56dimCD16dim Natural Killer (NK) cells: the forgotten population. HemaSphere. (2020) 4:e348. doi:&#xa0;10.1097/HS9.0000000000000348</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HS9.0000000000000348</ArticleId><ArticleId IdType="pmc">PMC7162090</ArticleId><ArticleId IdType="pubmed">32309785</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiow L, Rosen D, Brdi&#x10d;kov&#xe1; N, Xu Y, An J, Lanier LL, et al. . CD69 acts downstream of interferon-&#x3b1;/&#x3b2; to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature. (2006) 440:540&#x2013;4. doi:&#xa0;10.1038/nature04606</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04606</ArticleId><ArticleId IdType="pubmed">16525420</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay LK, Braun A, Macleod BL, Collins N, Tebartz C, Bedoui S, et al. . Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention. J Immunol. (2015) 194:2059&#x2013;63. doi:&#xa0;10.4049/jimmunol.1402256</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1402256</ArticleId><ArticleId IdType="pubmed">25624457</ArticleId></ArticleIdList></Reference><Reference><Citation>Hood SP, Foulds GA, Imrie H, Reeder S, McArdle SEB, Khan M, et al. . Phenotype and function of activated natural killer cells from patients with prostate cancer: patient-dependent responses to priming and IL-2 activation. Front Immunol. (2019) 9:3169. doi:&#xa0;10.3389/fimmu.2018.03169</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.03169</ArticleId><ArticleId IdType="pmc">PMC6362408</ArticleId><ArticleId IdType="pubmed">30761160</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemi E, Malarkannan S. Tissue-resident NK cells: development, maturation, and clinical relevance. Cancers (Basel). (2020) 12:1553. doi:&#xa0;10.3390/cancers12061553</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12061553</ArticleId><ArticleId IdType="pmc">PMC7352973</ArticleId><ArticleId IdType="pubmed">32545516</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Xiong H, Ning Z. Implications of NKG2A in immunity and immune-mediated diseases. Front Immunol. (2022) 13:960852. doi:&#xa0;10.3389/fimmu.2022.960852</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.960852</ArticleId><ArticleId IdType="pmc">PMC9399941</ArticleId><ArticleId IdType="pubmed">36032104</ArticleId></ArticleIdList></Reference><Reference><Citation>Carsetti R, Corrente F, Terreri S, Conti MG, Capponi C, Albano C. Comprehensive phenotyping of human peripheral blood B lymphocytes in healthy conditions. Cytometry. (2022) 101:131&#x2013;9. doi:&#xa0;10.1002/cyto.a.24507</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.24507</ArticleId><ArticleId IdType="pmc">PMC9546334</ArticleId><ArticleId IdType="pubmed">34664397</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliviero B, Varchetta S, Mele D, Mantovani S, Ludovisi S, Mondelli MU. Expansion of atypical memory B cells is a prominent feature of COVID-19. Cell Mol Immunol. (2020) 17:1101&#x2013;3. doi:&#xa0;10.1038/s41423-020-00542-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00542-2</ArticleId><ArticleId IdType="pmc">PMC7463104</ArticleId><ArticleId IdType="pubmed">32879471</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitfeld BD, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M, et al. . Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med. (2000) 192:1545&#x2013;51. doi:&#xa0;10.1084/jem.192.11.1545</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.192.11.1545</ArticleId><ArticleId IdType="pmc">PMC2193094</ArticleId><ArticleId IdType="pubmed">11104797</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellabona P, Consonni M, De Lalla C, Casorati G. Group 1 CD1-restricted T cells and the pathophysiological implications of self-lipid antigen recognition. Tissue Antigens. (2015) 86:393&#x2013;405. doi:&#xa0;10.1111/tan.12689</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.12689</ArticleId><ArticleId IdType="pubmed">26514448</ArticleId></ArticleIdList></Reference><Reference><Citation>Manfredi F, Abbati D, Cianciotti BC, Stasi L, Potenza A, Ruggiero E, et al. . Flow cytometry data mining by cytoChain identifies determinants of exhaustion and stemness in TCR-engineered T cells. Eur J Immunol. (2021) 51:1992&#x2013;2005. doi:&#xa0;10.1002/eji.202049103</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202049103</ArticleId><ArticleId IdType="pubmed">34081326</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieto-fontarigo JJ, Salgado FJ, San-j ME, Cruz MJ, Vald&#xe9;s L, P&#xe9;rez-d&#xed;az A, et al. . Expansion of different subpopulations of CD26 &#x2013;/low T cells in allergic and non-allergic asthmatics. Sci Rep. (2019) 9(1):7556. doi:&#xa0;10.1038/s41598-019-43622-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-43622-8</ArticleId><ArticleId IdType="pmc">PMC6525268</ArticleId><ArticleId IdType="pubmed">31101830</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengsch B, Seigel B, Flecken T, Blum HE, Thimme R. Human th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J Immunol. (2012) 188(11):5438&#x2013;47. doi:&#xa0;10.4049/jimmunol.1103801</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1103801</ArticleId><ArticleId IdType="pubmed">22539793</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero P, Zippelius A, Kurth I, Pittet J, Iancu EM, Corthesy P, et al. . Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J&#xa0;Immunol. (2007) 178:4112&#x2013;9. doi:&#xa0;10.4049/jimmunol.178.7.4112</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.7.4112</ArticleId><ArticleId IdType="pubmed">17371966</ArticleId></ArticleIdList></Reference><Reference><Citation>Galipeau Y, Greig M, Liu G, Driedger M, Miller M. Humoral responses and serological assays in SARS-coV-2 infections. Front Immunol. (2020) 11:610688. doi:&#xa0;10.3389/fimmu.2020.610688</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.610688</ArticleId><ArticleId IdType="pmc">PMC7775512</ArticleId><ArticleId IdType="pubmed">33391281</ArticleId></ArticleIdList></Reference><Reference><Citation>Newell KL, Clemmer DC, Cox JB, Kayode YI, Zoccoli-rodriguez V, Taylor HE, et al. . Switched and unswitched memory B cells detected during SARS-CoV-2 convalescence correlate with limited symptom duration. PloS One. (2021) 16(1):e0244855. doi:&#xa0;10.1371/journal.pone.0244855</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0244855</ArticleId><ArticleId IdType="pmc">PMC7843013</ArticleId><ArticleId IdType="pubmed">33507994</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. (2012) 10:221&#x2013;41. doi:&#xa0;10.1146/annurev-immunol-020711-074934</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-020711-074934</ArticleId><ArticleId IdType="pubmed">22224776</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma C, Bayry J. High risk of autoimmune diseases after COVID-19. Nat Rev Rheumatol. (2023) 19:399&#x2013;400. doi:&#xa0;10.1038/s41584-023-00964-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-023-00964-y</ArticleId><ArticleId IdType="pmc">PMC10096101</ArticleId><ArticleId IdType="pubmed">37046064</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lorenzo R, Conte C, Lanzani C, Benedetti F, Roveri L, Mazza MG, et al. . Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study. PloS One. (2020) 15:e0239570. doi:&#xa0;10.1371/journal.pone.0239570</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0239570</ArticleId><ArticleId IdType="pmc">PMC7556454</ArticleId><ArticleId IdType="pubmed">33052920</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lorenzo R, Cinel E, Cilla M, Compagnone N, Ferrante M, Falbo E, et al. . Physical and psychological sequelae at three months after acute illness in COVID-19 survivors. Panminerva Med. (2021) 65(3):312&#x2013;20. doi:&#xa0;10.23736/S0031-0808.21.04399-8</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S0031-0808.21.04399-8</ArticleId><ArticleId IdType="pubmed">34060280</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel AA, Zhang Y, Fullerton JN, Boelen L, Rongvaux A, Maini AA, et al. . The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. J Exp Med. (2017) 214:1913&#x2013;23. doi:&#xa0;10.1084/jem.20170355</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20170355</ArticleId><ArticleId IdType="pmc">PMC5502436</ArticleId><ArticleId IdType="pubmed">28606987</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamoutounour S, Guilliams M, Sanchis M, Liu H, Terhorst D, Sanchez C, et al. . Article origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. Immunity. (2013) 39(5):925&#x2013;38. doi:&#xa0;10.1016/j.immuni.2013.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.10.004</ArticleId><ArticleId IdType="pubmed">24184057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bain CC, Bravo-blas A, Scott CL, Perdiguero EG, Geissmann F, Henri S, et al. . Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat Immunol. (2014) 15(10):929&#x2013;37. doi:&#xa0;10.1038/ni.2967</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2967</ArticleId><ArticleId IdType="pmc">PMC4169290</ArticleId><ArticleId IdType="pubmed">25151491</ArticleId></ArticleIdList></Reference><Reference><Citation>Trzebanski S, Kim JS, Larossi N, Raanan A, Kancheva D, Bastos J, et al. . Classical monocyte ontogeny dictates their functions and fates as tissue macrophages. Immunity. (2024) 57(6):1225&#x2013;42. doi:&#xa0;10.1016/j.immuni.2024.04.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2024.04.019</ArticleId><ArticleId IdType="pubmed">38749446</ArticleId></ArticleIdList></Reference><Reference><Citation>Shambat SM, Gomez-Mejia A, Schweizer TA, Huemer M, Chang C-C, Acevedo C, et al. . Hyperinflammatory environment drives dysfunctional myeloid cell effector response to bacterial challenge in COVID-19. PLoS Pathog. (2022) 18(1):e1010176. doi:&#xa0;10.1371/journal.ppat.1010176</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010176</ArticleId><ArticleId IdType="pmc">PMC8782468</ArticleId><ArticleId IdType="pubmed">35007290</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantuano E, Brifault C, Lam MS, Azmoon P, Gilder AS, Gonias SL. LDL receptor-related protein-1 regulates NF &#x3ba; B and microRNA-155 in macrophages to control the inflammatory response. PNAS. (2016) 113(5):1369&#x2013;74. doi:&#xa0;10.1073/pnas.1515480113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1515480113</ArticleId><ArticleId IdType="pmc">PMC4747752</ArticleId><ArticleId IdType="pubmed">26787872</ArticleId></ArticleIdList></Reference><Reference><Citation>Albertini RA, Nicolas JC, Dato VA, Ferrer DG, Tinti ME, Capra RH, et al. . Decreased low-density lipoprotein receptor-related protein 1 expression in pro-inflammatory monocytes is associated with subclinical atherosclerosis. Front Cardiovasc Med. (2022) 9:949778. doi:&#xa0;10.3389/fcvm.2022.949778</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.949778</ArticleId><ArticleId IdType="pmc">PMC9360420</ArticleId><ArticleId IdType="pubmed">35958411</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui H, Jiang D, Banerjee S, Xie N, Kulkarni T, Liu R, et al. . Monocyte-derived alveolar macrophage apolipoprotein E participates in pulmonary fibrosis resolution. JCI Insights. (2020) 5:1&#x2013;15. doi:&#xa0;10.1172/jci.insight.134539</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.134539</ArticleId><ArticleId IdType="pmc">PMC7141408</ArticleId><ArticleId IdType="pubmed">32027623</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer B, Knoll R, Bonaguro L, ToVinh M, Raabe J, Astaburuaga-Garc&#x131;a R, et al. . Early IFN- a signatures and persistent dysfunction are distinguishing features of NK cells in severe ll Early IFN- a signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity. (2021) 54:2650&#x2013;69. doi:&#xa0;10.1016/j.immuni.2021.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.09.002</ArticleId><ArticleId IdType="pmc">PMC8416549</ArticleId><ArticleId IdType="pubmed">34592166</ArticleId></ArticleIdList></Reference><Reference><Citation>Witkowski M, Tizian C, Ferreira-gomes M, Niemeyer D, Jones TC, Heinrich F, et al. . Untimely TGF&#x3b2; responses in COVID-19 limit antiviral functions of NK cells. Nature. (2021) 600:295&#x2013;300. doi:&#xa0;10.1038/s41586-021-04142-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04142-6</ArticleId><ArticleId IdType="pubmed">34695836</ArticleId></ArticleIdList></Reference><Reference><Citation>Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56 bright natural killer (NK) cells: an important NK cell subset. Immunology. (2009) 126:458&#x2013;65. doi:&#xa0;10.1111/j.1365-2567.2008.03027.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2008.03027.x</ArticleId><ArticleId IdType="pmc">PMC2673358</ArticleId><ArticleId IdType="pubmed">19278419</ArticleId></ArticleIdList></Reference><Reference><Citation>Freud AG, Mundy-bosse BL, Yu J, Caligiuri MA. The broad spectrum of human natural killer cell diversity. Immunity. (2017) 47:820&#x2013;33. doi:&#xa0;10.1016/j.immuni.2017.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.10.008</ArticleId><ArticleId IdType="pmc">PMC5728700</ArticleId><ArticleId IdType="pubmed">29166586</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera L, Martin-Inaraja M, Santos S, Ingl&#xe9;s-Ferr&#xe1;ndiz M, Azkarate A, Perez-Vaquero MA, et al. . Identifying SARS-CoV-2 &#x2018;memory&#x2019; NK cells from COVID-19 convalescent donors for adoptive cell therapy. Immunology. (2022) 165:234&#x2013;49. doi:&#xa0;10.1111/imm.13432</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13432</ArticleId><ArticleId IdType="pmc">PMC8652867</ArticleId><ArticleId IdType="pubmed">34775592</ArticleId></ArticleIdList></Reference><Reference><Citation>Alrubayyi A, Touizer E, Hameiri-Bowen D, Charlton B, Gea-Mallorqu&#xed; E, Hussain N, et al. . Natural killer cell responses during SARS-CoV-2 infection and vaccination in people living with HIV-1. Sci Rep. (2023) 13:18994. doi:&#xa0;10.1038/s41598-023-45412-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-45412-9</ArticleId><ArticleId IdType="pmc">PMC10624865</ArticleId><ArticleId IdType="pubmed">37923825</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, et al. . Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. (2020) 369:eabc8511. doi:&#xa0;10.1126/science.abc8511</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc8511</ArticleId><ArticleId IdType="pmc">PMC7402624</ArticleId><ArticleId IdType="pubmed">32669297</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuwa HA, Shaw TN, Knight SB, Wemyss K, McClure FA, Pearmain L, et al. . Alterations in T and B cell function persist in convalescent COVID-19 patients. Med. (2021) 2:720&#x2013;35.e4. doi:&#xa0;10.1016/j.medj.2021.03.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.03.013</ArticleId><ArticleId IdType="pmc">PMC8011689</ArticleId><ArticleId IdType="pubmed">33821250</ArticleId></ArticleIdList></Reference><Reference><Citation>Quast I, Tarlinton D. B cell memory: understanding COVID-19. Immunity. (2021) 54:205&#x2013;10. doi:&#xa0;10.1016/j.immuni.2021.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.01.014</ArticleId><ArticleId IdType="pmc">PMC7826135</ArticleId><ArticleId IdType="pubmed">33513337</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaugel-Novoa M, Bourlet T, Paul S. Role of the humoral immune response during COVID-19: guilty or not guilty? Mucosal Immunol. (2022) 15:1170&#x2013;80. doi:&#xa0;10.1038/s41385-022-00569-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41385-022-00569-w</ArticleId><ArticleId IdType="pmc">PMC9530436</ArticleId><ArticleId IdType="pubmed">36195658</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Cla&#xeb;r L, et al. . IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Trans Med. (2021) 2223:1&#x2013;10. doi:&#xa0;10.1101/2020.06.10.20126532</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.10.20126532</ArticleId><ArticleId IdType="pmc">PMC7857408</ArticleId><ArticleId IdType="pubmed">33288662</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9; S, Azarias da Silva M, Picard M, Alleaume-Buteau A, Kundura L, Cezar R, et al. . Low quantity and quality of anti-spike humoral response is linked to CD4 T-cell apoptosis in COVID-19 patients. Cell Death Dis. (2022) 13:741. doi:&#xa0;10.1038/s41419-022-05190-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-022-05190-0</ArticleId><ArticleId IdType="pmc">PMC9419645</ArticleId><ArticleId IdType="pubmed">36030261</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz MJ, Siracusano G, Cottignies-Calamarte A, Tudor D, Real F, Zhu A, et al. . Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1&#x3b2; associate with COVID-19 fatal outcome: A cross-sectional analysis. Front Immunol. (2022) :842468. doi:&#xa0;10.3389/fimmu.2022.842468</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.842468</ArticleId><ArticleId IdType="pmc">PMC9560774</ArticleId><ArticleId IdType="pubmed">36248831</ArticleId></ArticleIdList></Reference><Reference><Citation>Dullaers M, Li D, Xue Y, Ni L, Gayet I, Morita R, et al. . A T cell-dependent mechanism for the induction of human mucosal homing immunoglobulin A-secreting plasmablasts. Immunity. (2009) 30:120&#x2013;9. doi:&#xa0;10.1016/j.immuni.2008.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2008.11.008</ArticleId><ArticleId IdType="pmc">PMC2659635</ArticleId><ArticleId IdType="pubmed">19144318</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu HQ, Sun BQ, Fang ZF, Zhao JC, Liu XY, Li YM, et al. . Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur Respir J. (2020) 56:2001526. doi:&#xa0;10.1183/13993003.01526-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01526-2020</ArticleId><ArticleId IdType="pmc">PMC7236821</ArticleId><ArticleId IdType="pubmed">32398307</ArticleId></ArticleIdList></Reference><Reference><Citation>Denis J, Garnier A, Cheutin L, Ferrier A, Timera H, Jarjaval F, et al. . Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disorders. Front Immunol. (2023) 14:1140714. doi:&#xa0;10.3389/fimmu.2023.1140714</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1140714</ArticleId><ArticleId IdType="pmc">PMC10031022</ArticleId><ArticleId IdType="pubmed">36969158</ArticleId></ArticleIdList></Reference><Reference><Citation>Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigaill J, et al. . A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol. (2021) 18:318&#x2013;27. doi:&#xa0;10.1038/s41423-020-00588-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00588-2</ArticleId><ArticleId IdType="pmc">PMC7786875</ArticleId><ArticleId IdType="pubmed">33408342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X, Angelo LS, Nicholson EG, Iwuchukwu OP, Cabral de Rezende W, Rajan A, et al. . Serum igG anti-SARS-coV-2 binding antibody level is strongly associated with igA and functional antibody levels in adults infected with SARS-coV-2. Front Immunol. (2021) 12:693462. doi:&#xa0;10.3389/fimmu.2021.693462</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.693462</ArticleId><ArticleId IdType="pmc">PMC8531527</ArticleId><ArticleId IdType="pubmed">34691016</ArticleId></ArticleIdList></Reference><Reference><Citation>Zervou FN, Louie P, Stachel A, Zacharioudakis IM, Ortiz-Mendez Y, Thomas K, et al. . SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection. J Med Virol. (2021) 93:5409&#x2013;15. doi:&#xa0;10.1002/jmv.27058</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27058</ArticleId><ArticleId IdType="pmc">PMC8242647</ArticleId><ArticleId IdType="pubmed">33932299</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakema JE, van Egmond M. The human immunoglobulin A Fc receptor Fc RI: a multifaceted regulator of mucosal immunity. Soc Mucosal Immunol. (2011) 4:612&#x2013;24. doi:&#xa0;10.1038/mi.2011.36</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2011.36</ArticleId><ArticleId IdType="pubmed">21937986</ArticleId></ArticleIdList></Reference><Reference><Citation>Regev-Yochay G, Lustig Y, Joseph G, Gilboa M, Barda N, Gens I, et al. . Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study. Lancet Microbe. (2023) 4:e309&#x2013;18. doi:&#xa0;10.1016/S2666-5247(23)00012-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00012-5</ArticleId><ArticleId IdType="pmc">PMC10030121</ArticleId><ArticleId IdType="pubmed">36963419</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Li Y, Kaplonek P, Gentili M, Fischinger S, Bowman KA, et al. . The kinetics of SARS-coV-2 antibody development is associated with clearance of RNAemia. mBio. (2022) 13:e0157722. doi:&#xa0;10.1128/mbio.01577-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.01577-22</ArticleId><ArticleId IdType="pmc">PMC9426503</ArticleId><ArticleId IdType="pubmed">35762593</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoepel W, Chen HJ, Geyer CE, Allahverdiyeva S, Manz XD, de Taeye SW, et al. . High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. Sci Transl Med. (2021) 13:eabf8654. doi:&#xa0;10.1126/scitranslmed.abf8654</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abf8654</ArticleId><ArticleId IdType="pmc">PMC8158960</ArticleId><ArticleId IdType="pubmed">33979301</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabetta E, Noviello M, Sciorati C, Vigan&#xf2; M, De Lorenzo R, Beretta V, et al. . A longitudinal analysis of humoral, T cellular response and influencing factors in a cohort of healthcare workers: Implications for personalized SARS-CoV-2 vaccination strategies. Front Immunol. (2023) 14:1130802. doi:&#xa0;10.3389/fimmu.2023.1130802</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1130802</ArticleId><ArticleId IdType="pmc">PMC10043299</ArticleId><ArticleId IdType="pubmed">36999012</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzavecchia A, Sallusto F. Progressive differentiation and selection of the fittest in the immune response. Nature. (2002) 2:982&#x2013;7. doi:&#xa0;10.1038/nri959</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri959</ArticleId><ArticleId IdType="pubmed">12461571</ArticleId></ArticleIdList></Reference><Reference><Citation>Gattinoni L, Speiser DE, Lichterfeld M, Bonini C. T memory stem cells in health and disease. Nat Med. (2017) 23:18&#x2013;27. doi:&#xa0;10.1038/nm.4241</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4241</ArticleId><ArticleId IdType="pmc">PMC6354775</ArticleId><ArticleId IdType="pubmed">28060797</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittelbrunn M, Kroemer G. Hallmarks of T cell aging. Nat Immunol. (2021) 22:687&#x2013;98. doi:&#xa0;10.1038/s41590-021-00927-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00927-z</ArticleId><ArticleId IdType="pubmed">33986548</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauri C, Menon M. Human regulatory B cells in health and disease: therapeutic potential. J Clin Invest. (2017) 127:772&#x2013;9. doi:&#xa0;10.1172/JCI85113</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI85113</ArticleId><ArticleId IdType="pmc">PMC5330739</ArticleId><ArticleId IdType="pubmed">28248202</ArticleId></ArticleIdList></Reference><Reference><Citation>Faccani C, Rotta G, Clemente F, Fedeli M, Abbati D, Manfredi F, et al. . Work flow for high-dimensional flow cytometry analysis of T cells from tumor metastases. Life Sci Alliance. (2022) 5:1&#x2013;18. doi:&#xa0;10.26508/lsa.202101316</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.202101316</ArticleId><ArticleId IdType="pmc">PMC9166301</ArticleId><ArticleId IdType="pubmed">35724271</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. (2020) 584:457&#x2013;62. doi:&#xa0;10.1038/s41586-020-2550-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2550-z</ArticleId><ArticleId IdType="pubmed">32668444</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranzenigo M, Pastori C, Siracusano G, Pariani E, Uberti-Foppa C, Lopalco L. Virological and serological discordant profiles in COVID-19 pneumonia: two atypical clinical cases. Front Immunol. (2020) 11:580867. doi:&#xa0;10.3389/fimmu.2020.580867</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.580867</ArticleId><ArticleId IdType="pmc">PMC7561713</ArticleId><ArticleId IdType="pubmed">33133098</ArticleId></ArticleIdList></Reference><Reference><Citation>Kursa MB. Feature selection with the Boruta package. J Stat Softw. (2010) 36:1&#x2013;13.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>